1. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial. (1st March 2022) Authors: Goebeler, M.; Bata‐Csörgő, Z.; De Simone, C.; Didona, B.; Remenyik, E.; Reznichenko, N.; Stoevesandt, J.; Ward, E.S.; Parys, W.; de Haard, H.; Dupuy, P.; Verheesen, P.; Schmidt, E.; Joly, P. Journal: British journal of dermatology Issue: Volume 186:Number 3(2022) Page Start: 429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial. (28th November 2021) Authors: Goebeler, M.; Bata‐Csörgő, Z.; De Simone, C.; Didona, B.; Remenyik, E.; Reznichenko, N.; Stoevesandt, J.; Ward, E.S.; Parys, W.; de Haard, H.; Dupuy, P.; Verheesen, P.; Schmidt, E.; Joly, P. Journal: British journal of dermatology Issue: Volume 186:Number 3(2022) Page Start: 429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗